Castle Biosciences Inc
CSTL40.090USD
-0.110-0.27%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
1.17BMarket Cap
LossP/E TTM
More Details of Castle Biosciences Inc Company
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
Castle Biosciences Inc Info
Ticker SymbolCSTL
Company nameCastle Biosciences Inc
IPO dateJul 25, 2019
CEOMaetzold (Derek J)
Number of employees761
Security typeOrdinary Share
Fiscal year-endJul 25
Address505 S Friendswood Drive
CityFRIENDSWOOD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code77546
Phone18667889007
Websitehttps://castlebiosciences.com/
Ticker SymbolCSTL
IPO dateJul 25, 2019
CEOMaetzold (Derek J)
Company Executives of Castle Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Derek J. Maetzold
Mr. Derek J. Maetzold
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
329.77K
-1.20%
Ms. Kristen M. Oelschlager
Ms. Kristen M. Oelschlager
Chief Operating Officer
Chief Operating Officer
109.51K
-14.74%
Mr. Tobin W. (Toby) Juvenal
Mr. Tobin W. (Toby) Juvenal
Chief Commercial Officer
Chief Commercial Officer
86.06K
-0.81%
Mr. Frank Stokes
Mr. Frank Stokes
Chief Financial Officer
Chief Financial Officer
43.33K
-11.06%
Ms. Ellen Goldberg
Ms. Ellen Goldberg
Independent Director
Independent Director
27.25K
+46.68%
Mr. Miles D. Harrison
Mr. Miles D. Harrison
Independent Director
Independent Director
21.96K
+65.25%
Mr. Rodney Cotton
Mr. Rodney Cotton
Independent Director
Independent Director
19.33K
+81.38%
Ms. Tiffany P. Olson
Ms. Tiffany P. Olson
Independent Director
Independent Director
--
--
Ms. Kimberlee S. Caple
Ms. Kimberlee S. Caple
Independent Director
Independent Director
--
--
Mr. Daniel Mark (Dan) Bradbury
Mr. Daniel Mark (Dan) Bradbury
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Derek J. Maetzold
Mr. Derek J. Maetzold
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
329.77K
-1.20%
Ms. Kristen M. Oelschlager
Ms. Kristen M. Oelschlager
Chief Operating Officer
Chief Operating Officer
109.51K
-14.74%
Mr. Tobin W. (Toby) Juvenal
Mr. Tobin W. (Toby) Juvenal
Chief Commercial Officer
Chief Commercial Officer
86.06K
-0.81%
Mr. Frank Stokes
Mr. Frank Stokes
Chief Financial Officer
Chief Financial Officer
43.33K
-11.06%
Ms. Ellen Goldberg
Ms. Ellen Goldberg
Independent Director
Independent Director
27.25K
+46.68%
Mr. Miles D. Harrison
Mr. Miles D. Harrison
Independent Director
Independent Director
21.96K
+65.25%
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
86.19M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
8.18%
The Vanguard Group, Inc.
7.39%
Principal Global Investors (Equity)
6.15%
Portolan Capital Management, L.L.C.
5.19%
Dimensional Fund Advisors, L.P.
5.05%
Other
68.04%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
8.18%
The Vanguard Group, Inc.
7.39%
Principal Global Investors (Equity)
6.15%
Portolan Capital Management, L.L.C.
5.19%
Dimensional Fund Advisors, L.P.
5.05%
Other
68.04%
Shareholder Types
Shareholders
Proportion
Investment Advisor
38.04%
Investment Advisor/Hedge Fund
32.84%
Hedge Fund
14.99%
Research Firm
3.12%
Individual Investor
2.62%
Private Equity
1.79%
Pension Fund
1.55%
Bank and Trust
0.52%
Corporation
0.05%
Other
4.49%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
389
26.96M
105.78%
+8.63K
2025Q3
399
26.96M
107.31%
-53.38K
2025Q2
398
27.00M
103.65%
+127.34K
2025Q1
409
26.52M
105.30%
-3.50M
2024Q4
404
26.78M
103.70%
+310.72K
2024Q3
401
26.78M
107.01%
+270.45K
2024Q2
387
26.46M
111.29%
-777.31K
2024Q1
393
27.23M
118.64%
-5.50M
2023Q4
395
25.58M
119.73%
+605.48K
2023Q3
403
24.88M
117.72%
+1.20M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
2.38M
8.2%
+65.63K
+2.84%
Jun 30, 2025
The Vanguard Group, Inc.
2.16M
7.43%
+112.73K
+5.52%
Jun 30, 2025
Principal Global Investors (Equity)
1.80M
6.2%
+331.10K
+22.56%
Jun 30, 2025
Portolan Capital Management, L.L.C.
1.49M
5.13%
-121.53K
-7.54%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.38M
4.75%
+177.78K
+14.81%
Jun 30, 2025
Braidwell LP
822.74K
2.84%
+457.49K
+125.25%
Jun 30, 2025
Nuveen LLC
772.05K
2.66%
+48.46K
+6.70%
Jun 30, 2025
State Street Investment Management (US)
707.69K
2.44%
-7.34K
-1.03%
Jun 30, 2025
Geode Capital Management, L.L.C.
689.93K
2.38%
+40.07K
+6.17%
Jun 30, 2025
Wasatch Global Investors Inc
1.05M
3.62%
+51.32K
+5.14%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Health Care Services ETF
1.3%
Inspire Small/Mid Cap ESG ETF
0.36%
iShares US Small Cap Value Factor ETF
0.29%
Royce Quant Small-Cap Quality Value ETF
0.27%
Harbor Human Capital Factor US Small Cap ETF
0.24%
iShares Micro-Cap ETF
0.14%
ProShares Ultra Nasdaq Biotechnology
0.14%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.12%
iShares U.S. Healthcare Providers ETF
0.12%
Texas Capital Texas Small Cap Equity Index ETF
0.11%
View more
State Street SPDR S&P Health Care Services ETF
Proportion1.3%
Inspire Small/Mid Cap ESG ETF
Proportion0.36%
iShares US Small Cap Value Factor ETF
Proportion0.29%
Royce Quant Small-Cap Quality Value ETF
Proportion0.27%
Harbor Human Capital Factor US Small Cap ETF
Proportion0.24%
iShares Micro-Cap ETF
Proportion0.14%
ProShares Ultra Nasdaq Biotechnology
Proportion0.14%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.12%
iShares U.S. Healthcare Providers ETF
Proportion0.12%
Texas Capital Texas Small Cap Equity Index ETF
Proportion0.11%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Castle Biosciences Inc?
The top five shareholders of Castle Biosciences Inc are:
BlackRock Institutional Trust Company, N.A. holds 2.38M shares, accounting for 8.20% of the total shares.
The Vanguard Group, Inc. holds 2.16M shares, accounting for 7.43% of the total shares.
Principal Global Investors (Equity) holds 1.80M shares, accounting for 6.20% of the total shares.
Portolan Capital Management, L.L.C. holds 1.49M shares, accounting for 5.13% of the total shares.
Dimensional Fund Advisors, L.P. holds 1.38M shares, accounting for 4.75% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.38M shares, accounting for 8.20% of the total shares.
The Vanguard Group, Inc. holds 2.16M shares, accounting for 7.43% of the total shares.
Principal Global Investors (Equity) holds 1.80M shares, accounting for 6.20% of the total shares.
Portolan Capital Management, L.L.C. holds 1.49M shares, accounting for 5.13% of the total shares.
Dimensional Fund Advisors, L.P. holds 1.38M shares, accounting for 4.75% of the total shares.
What are the top three shareholder types of Castle Biosciences Inc?
The top three shareholder types of Castle Biosciences Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Principal Global Investors (Equity)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Principal Global Investors (Equity)
How many institutions hold shares of Castle Biosciences Inc (CSTL)?
As of 2025Q4, 389 institutions hold shares of Castle Biosciences Inc, with a combined market value of approximately 26.96M, accounting for 105.78% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.53%.
What is the biggest source of revenue for Castle Biosciences Inc?
In FY2025Q2, the -- business generated the highest revenue for Castle Biosciences Inc, amounting to -- and accounting for --% of total revenue.
